Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

10/27/25 4:10:00 PM ET

$IMVT

$ROIV

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMVT alert in real time by email

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.

To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call.

About Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contacts:

Investors

Keyur Parekh

[email protected]

Media

Stephanie Lee

[email protected]

Get the next $IMVT alert in real time by email

Recent Analyst Ratings for

$IMVT

$ROIV

Company	Date	Price Target	Rating	Analyst
Immunovant Inc. $IMVT	10/14/2025	$16.00	Hold	Truist
Roivant Sciences Ltd. $ROIV	9/2/2025	$16.00	Buy	Citigroup
Roivant Sciences Ltd. $ROIV	7/10/2025	$19.00	Buy	Goldman
Immunovant Inc. $IMVT	7/10/2025	$18.00	Neutral	Goldman
Immunovant Inc. $IMVT	3/3/2025	$20.00	Hold	Jefferies
Immunovant Inc. $IMVT	1/3/2025		Outperform → Peer Perform	Wolfe Research
Immunovant Inc. $IMVT	10/10/2024	$36.00	Outperform	Raymond James
Immunovant Inc. $IMVT	10/9/2024	$47.00 → $53.00	Outperform	Oppenheimer

More analyst ratings

Recent Analyst Ratings for

$IMVT

$ROIV

Company	Date	Price Target	Rating	Analyst
Immunovant Inc. $IMVT	10/14/2025	$16.00	Hold	Truist
Roivant Sciences Ltd. $ROIV	9/2/2025	$16.00	Buy	Citigroup
Roivant Sciences Ltd. $ROIV	7/10/2025	$19.00	Buy	Goldman
Immunovant Inc. $IMVT	7/10/2025	$18.00	Neutral	Goldman
Immunovant Inc. $IMVT	3/3/2025	$20.00	Hold	Jefferies
Immunovant Inc. $IMVT	1/3/2025		Outperform → Peer Perform	Wolfe Research
Immunovant Inc. $IMVT	10/10/2024	$36.00	Outperform	Raymond James
Immunovant Inc. $IMVT	10/9/2024	$47.00 → $53.00	Outperform	Oppenheimer

More analyst ratings

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$IMVT
$ROIV

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$IMVT
$ROIV

$IMVT
$ROIV
Insider Purchases

CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

$IMVT
$ROIV
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Immunovant Inc.

SEC Form 144 filed by Roivant Sciences Ltd.

SEC Form S-3ASR filed by Roivant Sciences Ltd.

$IMVT
$ROIV
Insider Trading

President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85 and sold $4,044,000 worth of shares (200,000 units at $20.22) (SEC Form 4)

Chief Medical Officer Geffner Michael sold $49,383 worth of shares (2,595 units at $19.03), decreasing direct ownership by 1% to 217,958 units (SEC Form 4)

Chief Technology Officer Stout Jay S sold $47,956 worth of shares (2,520 units at $19.03), decreasing direct ownership by 1% to 200,814 units (SEC Form 4)

$IMVT
$ROIV
Press Releases

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025